JPH10510987A - 改良アデノウイルスベクターおよび生産者細胞 - Google Patents

改良アデノウイルスベクターおよび生産者細胞

Info

Publication number: JPH10510987A
Authority: JP; Japan
Prior art keywords: adenovirus; vector; dna sequence; dna; promoter
Prior art date: 1994-12-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP8519157A

Other languages

English (en)

Japanese (ja)

Inventor

カダン，マイケル

ゴジグリア，マリオ

トラップネル，ブルース

Original Assignee

ジェネティックセラピー，インコーポレイテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-12

Filing date

1995-12-07

Publication date

1998-10-27

1995-12-07 Application filed by ジェネティックセラピー，インコーポレイテッド filed Critical ジェネティックセラピー，インコーポレイテッド

1998-10-27 Publication of JPH10510987A publication Critical patent/JPH10510987A/ja

Status Pending legal-status Critical Current

Links

239000013598 vector Substances 0.000 title claims abstract description 220
241000701161 unidentified adenovirus Species 0.000 title claims abstract description 175
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 106
108090000623 proteins and genes Proteins 0.000 claims abstract description 93
241001135569 Human adenovirus 5 Species 0.000 claims abstract description 60
239000002245 particle Substances 0.000 claims abstract description 46
102000004169 proteins and genes Human genes 0.000 claims abstract description 37
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 21
229920001184 polypeptide Polymers 0.000 claims abstract description 20
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 20
241000193096 Human adenovirus B3 Species 0.000 claims abstract description 9
108010057856 Adenovirus E2 Proteins Proteins 0.000 claims abstract description 5
230000028709 inflammatory response Effects 0.000 claims abstract description 5
230000028993 immune response Effects 0.000 claims abstract description 3
108010056962 Adenovirus E4 Proteins Proteins 0.000 claims abstract 3
210000004027 cell Anatomy 0.000 claims description 125
108020004414 DNA Proteins 0.000 claims description 31
208000015181 infectious disease Diseases 0.000 claims description 30
238000004519 manufacturing process Methods 0.000 claims description 29
230000002458 infectious effect Effects 0.000 claims description 25
238000000034 method Methods 0.000 claims description 14
210000003527 eukaryotic cell Anatomy 0.000 claims description 10
230000001225 therapeutic effect Effects 0.000 claims description 9
108700026244 Open Reading Frames Proteins 0.000 claims description 8
238000001415 gene therapy Methods 0.000 claims description 7
108010087905 Adenovirus E1B Proteins Proteins 0.000 claims description 4
108010027410 Adenovirus E3 Proteins Proteins 0.000 claims description 4
108010024878 Adenovirus E1A Proteins Proteins 0.000 claims 2
239000013612 plasmid Substances 0.000 description 90
239000012634 fragment Substances 0.000 description 85
230000014509 gene expression Effects 0.000 description 33
230000037430 deletion Effects 0.000 description 31
238000012217 deletion Methods 0.000 description 31
241000700605 Viruses Species 0.000 description 25
108700019146 Transgenes Proteins 0.000 description 24
238000010276 construction Methods 0.000 description 23
230000006870 function Effects 0.000 description 20
230000001939 inductive effect Effects 0.000 description 18
238000010586 diagram Methods 0.000 description 17
238000001890 transfection Methods 0.000 description 14
239000003814 drug Substances 0.000 description 11
238000002744 homologous recombination Methods 0.000 description 11
239000011543 agarose gel Substances 0.000 description 10
230000006801 homologous recombination Effects 0.000 description 10
239000003862 glucocorticoid Substances 0.000 description 9
210000003494 hepatocyte Anatomy 0.000 description 9
238000012360 testing method Methods 0.000 description 9
229940124597 therapeutic agent Drugs 0.000 description 9
230000003612 virological effect Effects 0.000 description 9
101150029662 E1 gene Proteins 0.000 description 8
108700008625 Reporter Genes Proteins 0.000 description 8
108091027981 Response element Proteins 0.000 description 8
239000013604 expression vector Substances 0.000 description 8
239000002299 complementary DNA Substances 0.000 description 7
230000035772 mutation Effects 0.000 description 7
108700005077 Viral Genes Proteins 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
230000010076 replication Effects 0.000 description 6
108091008146 restriction endonucleases Proteins 0.000 description 6
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 5
238000003776 cleavage reaction Methods 0.000 description 5
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
229960003957 dexamethasone Drugs 0.000 description 5
230000029087 digestion Effects 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
239000013603 viral vector Substances 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 4
108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 4
108020004440 Thymidine kinase Proteins 0.000 description 4
108020005202 Viral DNA Proteins 0.000 description 4
229960000723 ampicillin Drugs 0.000 description 4
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
230000000692 anti-sense effect Effects 0.000 description 4
238000013459 approach Methods 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
239000003550 marker Substances 0.000 description 4
239000013600 plasmid vector Substances 0.000 description 4
238000000746 purification Methods 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000007017 scission Effects 0.000 description 4
239000007858 starting material Substances 0.000 description 4
108091026890 Coding region Proteins 0.000 description 3
241000701022 Cytomegalovirus Species 0.000 description 3
230000004543 DNA replication Effects 0.000 description 3
108700039887 Essential Genes Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 3
241000714474 Rous sarcoma virus Species 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
230000009977 dual effect Effects 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
208000006454 hepatitis Diseases 0.000 description 3
231100000283 hepatitis Toxicity 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
229950010131 puromycin Drugs 0.000 description 3
230000006798 recombination Effects 0.000 description 3
238000005215 recombination Methods 0.000 description 3
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
238000010361 transduction Methods 0.000 description 3
230000029812 viral genome replication Effects 0.000 description 3
108700026758 Adenovirus hexon capsid Proteins 0.000 description 2
102100022712 Alpha-1-antitrypsin Human genes 0.000 description 2
108010039209 Blood Coagulation Factors Proteins 0.000 description 2
102000015081 Blood Coagulation Factors Human genes 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
102100022641 Coagulation factor IX Human genes 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
206010010144 Completed suicide Diseases 0.000 description 2
208000032170 Congenital Abnormalities Diseases 0.000 description 2
101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 2
101150066038 E4 gene Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108010076282 Factor IX Proteins 0.000 description 2
108700039691 Genetic Promoter Regions Proteins 0.000 description 2
208000031220 Hemophilia Diseases 0.000 description 2
208000009292 Hemophilia A Diseases 0.000 description 2
101000907783 Homo sapiens Cystic fibrosis transmembrane conductance regulator Proteins 0.000 description 2
101000833492 Homo sapiens Jouberin Proteins 0.000 description 2
101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 2
102100024407 Jouberin Human genes 0.000 description 2
102000007330 LDL Lipoproteins Human genes 0.000 description 2
108010007622 LDL Lipoproteins Proteins 0.000 description 2
208000019693 Lung disease Diseases 0.000 description 2
241000713333 Mouse mammary tumor virus Species 0.000 description 2
101100364971 Mus musculus Scai gene Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 2
108010007131 Pulmonary Surfactant-Associated Protein B Proteins 0.000 description 2
108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 description 2
102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 description 2
102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 description 2
101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 2
241000700584 Simplexvirus Species 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
102000006601 Thymidine Kinase Human genes 0.000 description 2
239000000556 agonist Substances 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000003114 blood coagulation factor Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
238000010367 cloning Methods 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
229940079593 drug Drugs 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
238000012869 ethanol precipitation Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
229960004222 factor ix Drugs 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
230000005745 host immune response Effects 0.000 description 2
102000056427 human CFTR Human genes 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
210000005265 lung cell Anatomy 0.000 description 2
239000003580 lung surfactant Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000001466 metabolic labeling Methods 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
102220201851 rs143406017 Human genes 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000010186 staining Methods 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
230000026683 transduction Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
241001290610 Abildgaardia Species 0.000 description 1
102100036664 Adenosine deaminase Human genes 0.000 description 1
102000055025 Adenosine deaminases Human genes 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
108010027070 Apolipoproteins C Proteins 0.000 description 1
102000018655 Apolipoproteins C Human genes 0.000 description 1
108010025628 Apolipoproteins E Proteins 0.000 description 1
102000013918 Apolipoproteins E Human genes 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
101150029409 CFTR gene Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
206010010099 Combined immunodeficiency Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
206010019786 Hepatitis non-A non-B Diseases 0.000 description 1
206010019799 Hepatitis viral Diseases 0.000 description 1
101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 1
241000701109 Human adenovirus 2 Species 0.000 description 1
GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
-1 IL-1β Proteins 0.000 description 1
241000702377 Inovirus Species 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
241000726306 Irus Species 0.000 description 1
102000000853 LDL receptors Human genes 0.000 description 1
108010001831 LDL receptors Proteins 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
241000724832 Non-A, non-B hepatitis virus Species 0.000 description 1
101710087110 ORF6 protein Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 1
241000282806 Rhinoceros Species 0.000 description 1
101100406567 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ORT1 gene Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
101150064238 TR gene Proteins 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 description 1
101900150902 Varicella-zoster virus Thymidine kinase Proteins 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
239000003470 adrenal cortex hormone Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
230000003263 anti-adenoviral effect Effects 0.000 description 1
230000000636 anti-proteolytic effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
230000001746 atrial effect Effects 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
208000005980 beta thalassemia Diseases 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
208000022806 beta-thalassemia major Diseases 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000007698 birth defect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000007402 cytotoxic response Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000003831 deregulation Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000012215 gene cloning Methods 0.000 description 1
238000012224 gene deletion Methods 0.000 description 1
229930182478 glucoside Natural products 0.000 description 1
150000008131 glucosides Chemical class 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000012010 growth Effects 0.000 description 1
208000037824 growth disorder Diseases 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
229940097277 hygromycin b Drugs 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
229960001388 interferon-beta Drugs 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
210000005033 mesothelial cell Anatomy 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
210000003098 myoblast Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
230000005937 nuclear translocation Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000008520 organization Effects 0.000 description 1
210000004738 parenchymal cell Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
239000011148 porous material Substances 0.000 description 1
210000003240 portal vein Anatomy 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000008279 sol Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
210000003014 totipotent stem cell Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229940066528 trichloroacetate Drugs 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
238000009966 trimming Methods 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
201000001862 viral hepatitis Diseases 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000002845 virion Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/70—Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Hematology (AREA)
Zoology (AREA)
Obesity (AREA)
Wood Science & Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Psychiatry (AREA)
Molecular Biology (AREA)
Virology (AREA)
Microbiology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Biochemistry (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

JP8519157A 1994-12-12 1995-12-07 改良アデノウイルスベクターおよび生産者細胞 Pending JPH10510987A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US35508794A	1994-12-12	1994-12-12
US08/355,087		1994-12-12
US45840395A	1995-06-02	1995-06-02
US08/458,403		1995-06-02
PCT/US1995/015947 WO1996018418A1 (fr)	1994-12-12	1995-12-07	Vecteurs adenoviraux ameliores et cellules productrices

Publications (1)

Publication Number	Publication Date
JPH10510987A true JPH10510987A (ja)	1998-10-27

Family

ID=26998695

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP8519157A Pending JPH10510987A (ja)	1994-12-12	1995-12-07	改良アデノウイルスベクターおよび生産者細胞

Country Status (6)

Country	Link
EP (1)	EP0797454A4 (fr)
JP (1)	JPH10510987A (fr)
AU (1)	AU709498B2 (fr)
CA (1)	CA2206683A1 (fr)
NZ (1)	NZ300387A (fr)
WO (1)	WO1996018418A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2013539363A (ja) *	2010-08-16	2013-10-24	ソークインスティテュートフォーバイオロジカルスタディーズ	アデノウイルスの構築方法

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE336587T1 (de) *	1994-06-10	2006-09-15	Genvec Inc	Adenoviren-vektor systeme und zelllinien
DE69534166T2 (de) *	1994-10-28	2006-03-09	Trustees Of The University Of Pennsylvania	Rekombinanter adenovirus und methoden zu dessen verwendung
US6638762B1 (en)	1994-11-28	2003-10-28	Genetic Therapy, Inc.	Tissue-vectors specific replication and gene expression
US5998205A (en) *	1994-11-28	1999-12-07	Genetic Therapy, Inc.	Vectors for tissue-specific replication
IL116816A (en) *	1995-01-20	2003-05-29	Rhone Poulenc Rorer Sa	Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5872154A (en) *	1995-02-24	1999-02-16	The Trustees Of The University Of Pennsylvania	Method of reducing an immune response to a recombinant adenovirus
US6251957B1 (en)	1995-02-24	2001-06-26	Trustees Of The University Of Pennsylvania	Method of reducing an immune response to a recombinant virus
US5756283A (en) *	1995-06-05	1998-05-26	The Trustees Of The University Of Pennsylvania	Method for improved production of recombinant adeno-associated viruses for gene therapy
US6281010B1 (en)	1995-06-05	2001-08-28	The Trustees Of The University Of Pennsylvania	Adenovirus gene therapy vehicle and cell line
US6265212B1 (en)	1995-06-15	2001-07-24	Introgene B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
IL160406A0 (en)	1995-06-15	2004-07-25	Crucell Holland Bv	A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
US6783980B2 (en)	1995-06-15	2004-08-31	Crucell Holland B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
WO1998032860A1 (fr) *	1997-01-28	1998-07-30	Baxter International Inc.	Procede de production a haut rendement de vecteurs adenoviraux
US6403370B1 (en)	1997-02-10	2002-06-11	Genstar Therapeutics Corporation	Oncolytic/immunogenic complementary-adenoviral vector system
WO1998059063A2 (fr) *	1997-06-23	1998-12-30	University Of Saskatchewan	Genome de l'adenovirus bovin de type 3
US6670188B1 (en)	1998-04-24	2003-12-30	Crucell Holland B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
US6682929B2 (en)	2001-07-23	2004-01-27	Genvec, Inc.	Adenovector complementing cells
US20030158112A1 (en)	2002-02-15	2003-08-21	Johns Hopkins University School Of Medicine	Selective induction of apoptosis to treat ocular disease
US7364727B2 (en)	2002-07-22	2008-04-29	Cell Genesys, Inc.	Metastatic colon cancer specific promoter and uses thereof
US7977049B2 (en)	2002-08-09	2011-07-12	President And Fellows Of Harvard College	Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
CA2421269A1 (fr)	2002-08-09	2004-02-09	President And Fellows Of Harvard College	Methodes et compositions pour prolonger la duree de vie et accroitre la resistance au stress de cellules et d'organismes
US7026164B2 (en)	2003-07-03	2006-04-11	Cell Genesys, Inc.	Adenovirus packaging cell lines
CN1863918B (zh)	2003-10-02	2011-03-30	克鲁塞尔荷兰公司	用于重组腺病毒的包装细胞
SG11201507393TA (en)	2013-03-14	2015-10-29	Salk Inst For Biological Studi	Oncolytic adenovirus compositions
EP3188762A4 (fr)	2014-07-31	2018-01-10	The Board of Regents of the University of Oklahoma	Mutants de rpe65 de mammifère à activité isomérohydrolase élevée
KR102608590B1 (ko)	2014-09-24	2023-12-01	솔크 인스티튜트 포 바이올로지칼 스터디즈	종양 살상 바이러스 및 이의 사용방법
WO2017147265A1 (fr)	2016-02-23	2017-08-31	Salk Institute For Biological Studies	Dosage à haut débit pour mesurer la cinétique de réplication d'un adénovirus
WO2017147269A1 (fr)	2016-02-23	2017-08-31	Salk Institute For Biological Studies	Expression de gènes exogènes dans un adénovirus thérapeutique pour un effet minimal sur la cinétique virale
EP3532082A4 (fr)	2016-12-12	2020-08-26	Salk Institute for Biological Studies	Adénovirus synthétiques ciblant une tumeur et leurs utilisations
CN112292449A (zh)	2018-04-09	2021-01-29	萨克生物研究学院	具有增强的复制特性的溶瘤腺病毒组合物
MX2021014525A (es) *	2019-05-30	2022-03-17	Gritstone Bio Inc	Adenovirus modificados.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1024198A3 (fr) *	1992-12-03	2002-05-29	Genzyme Corporation	Vecteurs pseudo-adenoviraux pour la thérapie génique des hémophilies
FR2705686B1 (fr) *	1993-05-28	1995-08-18	Transgene Sa	Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
EP0710288B1 (fr) *	1993-06-10	2006-04-05	Genetic Therapy, Inc.	Vecteurs adenoviraux pour le traitement de l'hemophilie
ATE336587T1 (de) *	1994-06-10	2006-09-15	Genvec Inc	Adenoviren-vektor systeme und zelllinien
FR2724945B1 (fr) *	1994-09-27	1996-12-27	Centre Nat Rech Scient	Vecteurs viraux et utilisation en therapie genique
FR2726285B1 (fr) *	1994-10-28	1996-11-29	Centre Nat Rech Scient	Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5872005A (en) *	1994-11-03	1999-02-16	Cell Genesys Inc.	Packaging cell lines for adeno-associated viral vectors

1995
- 1995-12-07 WO PCT/US1995/015947 patent/WO1996018418A1/fr not_active Ceased
- 1995-12-07 CA CA002206683A patent/CA2206683A1/fr not_active Abandoned
- 1995-12-07 JP JP8519157A patent/JPH10510987A/ja active Pending
- 1995-12-07 EP EP95943705A patent/EP0797454A4/fr not_active Withdrawn
- 1995-12-07 AU AU45111/96A patent/AU709498B2/en not_active Ceased
- 1995-12-07 NZ NZ300387A patent/NZ300387A/en unknown

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2013539363A (ja) *	2010-08-16	2013-10-24	ソークインスティテュートフォーバイオロジカルスタディーズ	アデノウイルスの構築方法
JP2016198111A (ja) *	2010-08-16	2016-12-01	ソークインスティテュートフォーバイオロジカルスタディーズ	アデノウイルスの構築方法

Also Published As

Publication number	Publication date
AU709498B2 (en)	1999-09-02
AU4511196A (en)	1996-07-03
WO1996018418A1 (fr)	1996-06-20
NZ300387A (en)	2001-07-27
CA2206683A1 (fr)	1996-06-20
EP0797454A4 (fr)	2001-12-05
EP0797454A1 (fr)	1997-10-01

Publication	Publication Date	Title
JPH10510987A (ja)	1998-10-27	改良アデノウイルスベクターおよび生産者細胞
US6156497A (en)	2000-12-05	Recombinase-mediated generation of adenoviral vectors
Lieber et al.	1996	Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo
EP1032696B1 (fr)	2006-06-14	Vecteur pour replication et expression genique a specificite tissulaire
KR100449181B1 (ko)	2005-01-24	유전자요법에사용할수있는사람의재조합아데노바이러스패키징시스템
Zhou et al.	1996	Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted
AU707208B2 (en)	1999-07-08	Method for the preparation of a viral vector by intermolecular homologous recombination
JP3565859B2 (ja)	2004-09-15	改良されたアデノウイルスおよびその使用法
JP3299761B2 (ja)	2002-07-08	相補的なアデノウィルスベクター系と細胞株
CA2278616C (fr)	2012-03-20	Adenovirus comprenant des proteines d'hexon modifiees
WO1997025446A9 (fr)	1997-10-09	Generation de vecteurs adenoviraux a mediation de recombinase
AU716045B2 (en)	2000-02-17	Vectors for tissue-specific replication
US20030118570A1 (en)	2003-06-26	Vectors for tissue-specific replication
WO1996017053A9 (fr)	1996-07-25	Vecteurs de replication a specificite tissulaire
JPH10506542A (ja)	1998-06-30	遺伝子治療用ウイルスベクターおよび系統
JP2000106875A (ja)	2000-04-18	目的遺伝子の発現を改善するためのアデノウイルスｅ４リ―ディングフレ―ムの使用
JP2007530004A (ja)	2007-11-01	疾患を処置するためのサブグループｂアデノウイルスベクター
JP2002528128A (ja)	2002-09-03	組換えアデノウイルスベクターの増殖のためのアデノウイルス必須機能を発現するウシ細胞
AU3345801A (en)	2001-06-21	Recombinase-mediated generation of adenoviral vectors